{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T18:08:29Z","timestamp":1781806109101,"version":"3.54.5"},"reference-count":22,"publisher":"Wiley","license":[{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cardiacare Sponsored Optimizing Antithrombotic Research Fund","award":["BJUHFCSOARF201901-19"],"award-info":[{"award-number":["BJUHFCSOARF201901-19"]}]},{"name":"Cardiacare Sponsored Optimizing Antithrombotic Research Fund","award":["2016YFC1031301"],"award-info":[{"award-number":["2016YFC1031301"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"crossref","award":["BJUHFCSOARF201901-19"],"award-info":[{"award-number":["BJUHFCSOARF201901-19"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"crossref","award":["2016YFC1031301"],"award-info":[{"award-number":["2016YFC1031301"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2020,4,25]]},"abstract":"<jats:p><jats:italic>Aim<\/jats:italic>. To evaluate the clinical impact of <jats:italic>\u03b2<\/jats:italic>-blocker in patients with adequate left ventricular ejection function (LVEF) who underwent percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). <jats:italic>Methods<\/jats:italic>. A total of 10,724 consecutive patients who underwent PCI throughout 2013 were prospectively enrolled in the study. Among these, we analyzed 5,631 ACS patients who were discharged with <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\"><mml:mtext>LVEF<\/mml:mtext><mml:mo>\u2265<\/mml:mo><mml:mn>40<\/mml:mn><mml:mi>%<\/mml:mi><\/mml:math>. Patients were then compared according to the <jats:italic>\u03b2<\/jats:italic>-blocker prescription at discharge. <jats:italic>Results<\/jats:italic>. During a 2-year follow-up, no significant association was observed of <jats:italic>\u03b2<\/jats:italic>-blocker use with all-cause mortality (with <jats:italic>\u03b2<\/jats:italic>-blockers 47\/5,043 (0.9%) <jats:italic>vs.<\/jats:italic> without <jats:italic>\u03b2<\/jats:italic>-blocker use 8\/588 (1.4%); hazard ratio (HR) 0.762, 95% confidence interval 0.36 to 1.64; <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\"><mml:mi>P<\/mml:mi><mml:mo>=<\/mml:mo><mml:mn>0.485<\/mml:mn><\/mml:math>), cardiac death, myocardial infarction (MI), or major adverse cardiovascular and cerebrovascular events. Subgroup analysis demonstrated that the <jats:italic>\u03b2<\/jats:italic>-blocker use at discharge reduced the 2-year mortality in patients with unstable angina (UA) (HR 0.42, 95% CI 0.19 to 0.94, <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\"><mml:mi>P<\/mml:mi><mml:mo>=<\/mml:mo><mml:mn>0.034<\/mml:mn><\/mml:math>). Landmark analysis at 1 year showed that patients with UA who were discharged with <jats:italic>\u03b2<\/jats:italic>-blockers had lower mortality (HR 0.17, 95% CI 0.04-0.65, <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\"><mml:mi>P<\/mml:mi><mml:mo>=<\/mml:mo><mml:mn>0.010<\/mml:mn><\/mml:math>) and cardiac death (HR 0.12, 95% CI 0.01-0.99, <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M5\"><mml:mi>P<\/mml:mi><mml:mo>=<\/mml:mo><mml:mn>0.049<\/mml:mn><\/mml:math>) than those discharged without <jats:italic>\u03b2<\/jats:italic>-blockers. However, the benefit was lost beyond 1 year. No differences in outcomes were recorded in the AMI or overall population. <jats:italic>Conclusions<\/jats:italic>. We present that <jats:italic>\u03b2-<\/jats:italic>blocker significantly lowers the rate of all-cause death up to 1 year, in UA patients who have undergone PCI and have adequate LVEF. Its role in patients with AMI also deserves further exploration.<\/jats:p>","DOI":"10.1155\/2020\/4351469","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T23:31:45Z","timestamp":1587857505000},"page":"1-10","source":"Crossref","is-referenced-by-count":7,"title":["Association of <i>\u03b2<\/i>-Blocker Therapy at Discharge with Clinical Outcomes after Acute Coronary Syndrome in Patients without Heart Failure"],"prefix":"10.1155","volume":"2020","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9376-037X","authenticated-orcid":true,"given":"Yan","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Cardiology, The State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-fang","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-lin","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-jin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1165-7302","authenticated-orcid":true,"given":"Bo","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-5103","authenticated-orcid":true,"given":"Jin-qing","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.11.019"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.017"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs215"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx393"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7200.1730"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f55"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1159\/000431077"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4801"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.10.001"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.05.032"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2003.07.023"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31823ba622"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e318235eb4d"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs184"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.06.004"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.03.578"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.02.057"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004190"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2013.12.206"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.10.026"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2009.188607"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cdtp\/2020\/4351469.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cdtp\/2020\/4351469.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cdtp\/2020\/4351469.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T23:31:48Z","timestamp":1587857508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/cdtp\/2020\/4351469\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,25]]},"references-count":22,"alternative-id":["4351469","4351469"],"URL":"https:\/\/doi.org\/10.1155\/2020\/4351469","relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,25]]}}}